This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina
by Zacks Equity Research
Molina Healthcare partners with Aeroflow Health to expand nutrition counseling and diabetes care for the former's Commercial and Medicare members in South Carolina.
MOHPositive Net Change ADUSNegative Net Change COLLNegative Net Change MEDPPositive Net Change
medical
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
by Zacks Equity Research
GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
GSKPositive Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs medical
Hims & Hers Expands Its Technology-Driven Personalized Virtual Care
by Debanjana Dey
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
TDOCNegative Net Change HIMSNegative Net Change DOCSNegative Net Change
medical medical-devices
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
by Zacks Equity Research
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
RHHBYNegative Net Change LLYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
by Ahan Chakraborty
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.
NVOPositive Net Change LLYPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
ANIPPositive Net Change
biotechnology biotechs medical
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?
by Zacks Equity Research
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
NVOPositive Net Change LLYPositive Net Change WVENegative Net Change
biotechs medical pharmaceuticals
ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries
by Zacks Equity Research
Intuitive Surgical broadens its da Vinci SP system with FDA clearance for three new surgeries, expanding its role in minimally invasive care.
ISRGNegative Net Change EDAPNo Net Change VCYTNegative Net Change AORTPositive Net Change
medical medical-devices
Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?
by Indrajit Bandyopadhyay
Intuitive Surgical grapples with a GLP-1-driven bariatric slump but leans on strong general surgery gains and rising da Vinci 5 adoption.
MDTNegative Net Change ISRGNegative Net Change TFXNegative Net Change
medical medical-devices
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
by Zacks Equity Research
WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.
BSXNegative Net Change ISRGNegative Net Change WSTPositive Net Change MEDPPositive Net Change
medical medical-devices
Should You Continue to Hold EW Stock in Your Portfolio?
by Zacks Equity Research
Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
EWPositive Net Change ILMNPositive Net Change PODDNegative Net Change BTSGPositive Net Change
medical medical-devices
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
by Moumi Mondal
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
ABTPositive Net Change BSXNegative Net Change MDTNegative Net Change
medical medical-devices
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
by Sundeep Ganoria
ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
BEAT Secures FDA Nod for First Cable-Free At-Home 12-Lead ECG System
by Zacks Equity Research
HeartBeam's FDA clearance for its cable-free at-home 12-lead ECG marks a pivotal step toward commercialization and broader cardiac-care adoption.
BSXNegative Net Change ISRGNegative Net Change BEATPositive Net Change MEDPPositive Net Change
medical medical-devices
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.
BSXNegative Net Change ISRGNegative Net Change FMSNo Net Change MEDPPositive Net Change
medical medical-devices
Tempus AI's Strategic Push to Expand Beyond Oncology
by Sridatri Sarkar
TEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its diagnostic reach.
NNOXNegative Net Change GEHCPositive Net Change TEMNegative Net Change
medical
Best Value Stock to Buy for December 11th
by Zacks Equity Research
UHS made it to the Zacks Rank #1 (Strong Buy) value stock list on December 11, 2025.
UHSPositive Net Change
medical
JRVR, BCAL and More Are Now Strong Buy Stocks (Dec. 11)
by Zacks Equity Research
PDLB, JRVR, BCAL, UHS and WAY have been added to the Zacks Rank #1 (Strong Buy) List on December 11th, 2025.
UHSPositive Net Change JRVRPositive Net Change PDLBPositive Net Change BCALNegative Net Change WAYPositive Net Change
computers finance insurance medical
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
by Zacks Equity Research
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.
ISRGNegative Net Change VCYTNegative Net Change PLSENegative Net Change AORTPositive Net Change
medical medical-devices
Fed Watch: Will Jerome Powell Goose the Stock Market?
by Ethan Feller
Healthcare and Energy stocks have perked up ahead of this meeting--should investors favor defensive positioning going forward?
XLENegative Net Change XLKNegative Net Change XLVPositive Net Change
energy medical tech-stocks
Behind the Curtain: How UnitedHealth is Rewriting its Own Rules
by Rajshree Sipani
UNH is reshaping its model with tech-driven, integrated care as Optum's growth and rising revenues redefine its strategy.
UNHPositive Net Change HUMPositive Net Change ELVPositive Net Change
artificial-intelligence insurance medical smart-health
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
by Ahan Chakraborty
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia
by Zacks Equity Research
Teva files an NDA seeking FDA approval for its once-monthly olanzapine LAI for the treatment of adults with schizophrenia.
SNYPositive Net Change TEVAPositive Net Change ANIPPositive Net Change CSTLNegative Net Change
medical
Implied Volatility Surging for Prestige Consumer Stock Options
by Zacks Equity Research
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
PBHNegative Net Change
medical
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
Cencora's U.S. Healthcare Solutions strength, RCA gains, and raised FY25 guidance underscore its accelerating growth momentum.
ISRGNegative Net Change CORPositive Net Change VCYTNegative Net Change MEDPPositive Net Change
medical medical-devices